Revasc

Revasc Uses, Dosage, Side Effects, Food Interaction and all others data.

Revasc is a direct inhibitor of human thrombin. It has a protein structure that is similar to that of hirudin, the naturally occurring anticoagulant present in the peripharyngeal glands in the medicinal leech, Hirudo medicinalis. Hirudin is a single polypeptide chain of 65 amino acids residues and contains three disulfide bridges. Revasc has a chemical formula of C287H440N80O110S6 with a molecular weight of 6963.52.

It is mainly indicated for the prevention of deep vein thrombosis in hip replacement surgery patients.Common side effects include: Bleeding gums, collection of blood under the skin, coughing up blood, deep, dark purple bruise and difficulty with breathing or swallowing.

Revasc results in dose-dependent prolongation of the activated partial thromboplastin time (aPTT).

Table Of contents

• Revasc
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	Revasc
Availability	Discontinued
Generic	Desirudin
Desirudin Other Names	63-Desulfohirudin, 63-Desulfohirudin (Hirudo Medicinalis Isoform HV1), 63-Desulfohirudin (recombinant), Desirudin, Desirudin recombinant, Desirudina, Hirudin desirudin
Related Drugs	Xarelto, Eliquis, enoxaparin, apixaban, rivaroxaban, heparin
Type
Formula	C287H440N80O110S6
Protein binding	Desirudin binds specifically and directly to thrombin, forming an extremely tight, non-covalent complex with an inhibitionconstant of approximately 2.6 x 10-13 M. Thus, free or protein bound desirudin immediately binds circulating thrombin.
Groups	Approved
Therapeutic Class
Manufacturer
Available Country	France, Italy, Netherlands, Portugal, Spain
Last Updated:	September 19, 2023 at 7:00 am

Uses

Indicated as prophylaxis of deep vein thrombosis for patients undergoing hip replacement surgery.

Revasc is also used to associated treatment for these conditions: Deep Vein Thrombosis

How Revasc works

Revasc is a direct, highly selective thrombin inhibitor. Reversibly binds to the active thrombin site of free and clot-associated thrombin. Inhibits fibrin formation, activation of coagulation factors V, VII, and XIII, and thrombin-induced platelet aggregation resulting in a dose-dependent prolongation of the activated partial thromboplastin time (aPTT).

Toxicity

No data available.

Food Interaction

• Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.

Revasc Drug Interaction

Major: bivalirudin, bivalirudin, warfarin, warfarin, enoxaparin, enoxaparin, dabigatran, dabigatranUnknown: bevacizumab, bevacizumab, levetiracetam, levetiracetam, temozolomide, temozolomide, emtricitabine / tenofovir, emtricitabine / tenofovir, valacyclovir, valacyclovir, acyclovir, acyclovir

Revasc Disease Interaction

Major: active bleeding

Volume of Distribution

0.25 L/kg.

Elimination Route

Absorption is complete after subcutaneous administration. Time to peak in plasma is 1 to 3 hours.

Half Life

~2 hours.

Clearance

1.5 to 2.7 mL/min/kg.

Elimination Route

Urine (40% to 50% as unchanged drug).

Innovators Monograph

You find simplified version here Revasc